BUY MBP DARATUMUMAB CONCN SOL DARZALEX-100MG VIAL BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Daratumumab is a targeted cancer medicine used to treat multiple myeloma, a cancer of plasma cells in the bone marrow. Daratumumab is usually prescribed when multiple myeloma has returned, not responded fully to earlier treatment, or as part of combination therapy. If you have been prescribed daratumumab, it is normal to want a clear explanation of what daratumumab does, how it is given and what you may experience during treatment.

Daratumumab is a monoclonal antibody. It works by attaching to a protein called CD38, which is found in high amounts on myeloma cells. Once daratumumab binds to CD38, it helps the immune system recognise and destroy these cancer cells. Daratumumab may also directly interfere with the survival of myeloma cells. Because daratumumab targets a specific protein, it works differently from traditional chemotherapy.

Daratumumab concentrated solution is prepared and administered by trained healthcare professionals. You will not handle or prepare daratumumab yourself. Daratumumab is given either as an intravenous infusion or as a subcutaneous injection, depending on the formulation used. Infusions are given in hospital or a specialist clinic. The first dose of daratumumab is usually given more slowly because infusion-related reactions are most likely to occur with the first treatment. Later doses are often given more quickly if the first dose is well tolerated.

Daratumumab is often given weekly at first, then less frequently over time. The exact schedule depends on your treatment plan and whether daratumumab is being used alone or with other medicines. It is important to attend all scheduled appointments so daratumumab can work effectively.

One of the most important things to know about daratumumab is infusion-related reactions. These reactions usually happen during or shortly after the first daratumumab dose. Symptoms may include runny or blocked nose, cough, throat irritation, shortness of breath, wheezing, fever, chills, headache, nausea or low blood pressure. You will be given medicines before daratumumab to reduce the risk of these reactions, and nurses will monitor you closely during treatment. If you feel unwell at any point during the infusion, you should inform the nurse immediately.

After daratumumab treatment, some people experience tiredness, nausea, back pain, muscle aches or mild fever. These symptoms are usually manageable and improve with time. Rest, hydration and simple pain relief such as paracetamol can help if approved by your doctor.

Daratumumab can affect blood counts, particularly lowering red blood cells, white blood cells or platelets. Your doctor will arrange regular blood tests to monitor this. You should be alert for symptoms such as increased tiredness, shortness of breath, easy bruising, bleeding, fever or signs of infection. Any fever while on daratumumab should be reported promptly.

Daratumumab can increase the risk of infections, especially respiratory infections. Practising good hand hygiene, avoiding contact with people who are unwell and reporting early signs of infection are important while receiving daratumumab.

A unique point about daratumumab is that it can interfere with blood compatibility testing. Daratumumab can affect blood grouping and cross-matching tests for several months after treatment. It is very important that all healthcare providers, including emergency staff, know that you are receiving or have received daratumumab. You may be given a patient alert card to carry with you for this reason.

Daratumumab can also cause reactivation of certain viral infections, such as hepatitis B. Your doctor will check your blood tests before starting treatment. If you have a history of hepatitis, make sure your medical team is aware.

Some patients experience mild injection site reactions if receiving subcutaneous daratumumab, such as redness, swelling or itching. These usually settle within a few days.

Daratumumab does not usually cause hair loss. It may be combined with other medicines that have their own side effects, so it is important to understand which effects are from daratumumab and which may be from other treatments.

Daratumumab should not be used during pregnancy. Effective contraception is recommended during treatment and for the period advised by your doctor afterwards. If pregnancy is suspected, medical advice should be sought immediately.

Vaccinations may need special consideration while on daratumumab. Live vaccines are generally avoided. Always check with your healthcare team before receiving any vaccines.

As your pharmacist, my role is to help you understand what daratumumab is for, what side effects to watch for, and when to seek medical advice. Your doctor manages dosing, monitoring and treatment decisions, but if anything about daratumumab feels unclear or concerning, please ask.

Daratumumab has become an important treatment option in multiple myeloma. Understanding how daratumumab works and what to expect helps you stay informed and actively involved in your care.

ChatGPT can make mistakes. Check importa